Incannex Healthcare Australian Stock Exchange
Market Closed -
Other stock markets
|5-day change||1st Jan Change|
|Dec. 06||Incannex Healthcare Inc Update on Ihl-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea||CI|
More about the company
Incannex Healthcare Limited is an Australia-based clinical-stage pharmaceutical development company. The Company is engaged in the research and development associated with medicinal cannabinoid and psychedelic pharmaceutical products and therapies. The Company targets five indications: obstructive sleep apnea (OSA), traumatic brain injury and concussion (TBI), rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and inflammatory lung conditions. Its drug candidates include IHL-42X, IHL-216A, Psilocybin-assisted psychotherapy for general anxiety disorder (Psi-GAD) and IHL-675A. Its IHL-42X is a cannabinoid combination product for treatment of OSA. Its IHL-675A comprises a combination of hydroxychloroquine and CBD for prevention and treatment of inflammatory lung conditions, rheumatoid arthritis and inflammatory bowel diseases. IHL-216A is a cannabinoid combination product for the treatment of TBI. It is investigating the use of psilocybin-assisted psychotherapy to treat GAD.
2024-02-26 - Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
- Stock Incannex Healthcare Inc.
- Stock Incannex Healthcare - Australian Stock Exchange
- News Incannex Healthcare
- Incannex Opens Patient Registration for Psychedelics-Assisted Treatment Program; Shares Rise 5%